Connect your AI

Absci Corporation ABSI Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

SchrodingerSDGR

——

Recursion Pharmaceuticals, Inc.RXRX

——

BridgeBio PharmaBBIO

——

ZymeworksZYME

——

BioCryst PharmaceuticalsBCRX

——

Guardant HealthGH

——

Other financials

Income statement

Revenue$215.0K-81.8%

Operating income-$30.8M-11.2%

Net income-$29.6M-12.3%

EPS (diluted)-$0.19+9.5%

Balance sheet

Cash & equivalents$9.7M-84.9%

Total debt$4.0M-37.2%

Total equity$172.0M-13.5%

Total assets$195.6M-15.9%

Cash flow

Operating cash flow-$26.3M-20.5%

CapEx$30.0K+20.0%

Free cash flow-$26.3M-20.5%

Valuation

Market cap$1.57B+43.6%

Enterprise value$1.57B+73.1%

P/S855.5×+628×

Profitability

Operating margin-6,723%-14,525pp

Net margin-6,450.8%-13,699pp

FCF margin-5,365.2%-9,300pp

Returns & leverage

Return on equity-63.9%+28.0pp

Debt / equity0×0.0×

Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Absci Corporation's deferred revenue, net of current portion?: Absci Corporation (ABSI) reported deferred revenue, net of current portion of $641K in Q1 2026.